Search
for
Sort by
Research 30 of 1000+
- Pharmacogenomic variation and chemotherapy-related toxicity profiles in pediatric patients with cancer in Tanzania: a cross-sectional study
- Chemotherapy-related adverse effects with anthracycline and taxane-containing regimens in patients with localized Breast cancer: a descriptive study
- Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆
- Management of Skin Toxicities in Cancer Treatment: An Australian/New Zealand Perspective
- Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team
- Novel anti-Mullerian hormone receptor 2 binding peptide prevents chemotherapy-related ovarian follicle loss in a mouse model
- Targeted Therapy– and Chemotherapy-Associated Skin Toxicities: Systematic Review and Meta-Analysis
- The effect and mechanism of YH0618 granule on chemotherapy- induced hair loss in patients with breast cancer: study protocol for a randomized, double-blind, multi-center clinical trial
- Effect and mechanism of YH0618 granule on chemotherapy- induced hair loss in patients with breast cancer: study protocol for a randomized, double-blind, multi-center clinical trial
- 1400 Low-intensity ultrasound protects human scalp hair follicles from taxane-induced toxicity
- High incidence of severe hand–foot syndrome during capecitabine–docetaxel combination chemotherapy
- Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy
- Effectiveness and safety of standard chemotherapy in older patients with ovarian cancer: a retrospective analysis by age group and treatment regimen
- A Cross-Sectional Study on Symptom Burden, Malnutrition Risk, Psychological Distress and Palliative Outcomes in Cancer Patients Undergoing Chemotherapy
- Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
- Supportive Oncodermatology: Addressing dermatologic adverse events associated with oncologic therapies
- S-l Combined with Paclitaxel as Second-line Chemotherapy for Advanced Gastric Cancer
- Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment
- A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA): Final study results
- Hypertrichosis, trichomegaly, and androgenic alopecia related to cetuximab treatment
- Mechanisms underlying select chemotherapeutic-agent-induced neuroinflammation and subsequent neurodegeneration
- The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?
- Aldesleukin
- THE GLOBAL CHALLENGE OF CHEMOTHERAPY TOXICITY: RETHINKING SUPPORTIVE CARE IN MODERN ONCOLOGY
- Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients
- Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women’s cancers. Results of a prospective study
- The Enigma of the Stigma of Hair Loss: Why is Cancer-Treatment Related Alopecia so Traumatic for Women?
- Chemotherapy-induced toxicity—a secondary effect caused by released DNA?
- Effect of a medicinal and edible decoction YH0618 on chemotherapy-induced dermatologic toxicity: a randomized controlled trial
- Dermatological adverse events with taxane chemotherapy